ANAB - ANAPTYSBIO, INC
IEX Last Trade
14.265
0.415 2.909%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$13.85
0.42
3.00%
Fundamental analysis
14%
Profitability
8%
Dept financing
18%
Liquidity
75%
Performance
4%
Performance
5 Days
-4.54%
1 Month
-42.37%
3 Months
-57.05%
6 Months
-41.76%
1 Year
-33.03%
2 Year
-52.48%
Key data
Stock price
$14.26
DAY RANGE
N/A - N/A
52 WEEK RANGE
$14.59 - $41.31
52 WEEK CHANGE
-$36.46
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Daniel R. Faga
Region: US
Website: anaptysbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: anaptysbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AnaptysBio, Inc. engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
Recent news